CD80 Polyclonal Antibody

Elabscience
Product Code: E-AB-13083
Product Group: Primary Antibodies
Supplier: Elabscience
CodeSizePrice
E-AB-13083-20uL20uL£125.00
Quantity:
E-AB-13083-60uL60uL£172.00
Quantity:
E-AB-13083-120uL120uL£237.00
Quantity:
E-AB-13083-200uL200uL£344.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Immunohistochemistry (IHC)
Shipping:
Ice packs
Storage:
-20°C

Images

1 / 2
Immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using CD80 Polyclonal Antibody at dilution 1:50
2 / 2
Immunohistochemistry of paraffin-embedded Human gastric cancer tissue using CD80 Polyclonal Antibody at dilution 1:50

Immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using CD80 Polyclonal Antibody at dilution 1:50
Immunohistochemistry of paraffin-embedded Human gastric cancer tissue using CD80 Polyclonal Antibody at dilution 1:50

Documents

Further Information

Abbreviation:
CD80
Background:
The protein encoded by this gene is a membrane receptor that is activated by the binding of CD28 or CTLA-4. The activated protein induces T-cell proliferation and cytokine production. This protein can act as a receptor for adenovirus subgroup B and may play a role in lupus neuropathy.
Buffer:
PBS with 0.05% sodium azide and 50% glycerol, PH7.4
Concentration:
0.8 mg/mL
Conjugation:
Unconjugated
Dilution:
IHC 1:50-1:200
Immunogen:
Synthetic peptide of human CD80
Purification method:
Affinity purification
Target Synonym:
Activation B7-1 antigen;B lymphocyte activation antigen B7;B7;B7-1;B7-1 antigen;B7.1;BB1;CD28 antigen ligand 1;CD28LG;CD28LG1;CD80;CD80 antigen (CD28 antigen ligand 1;B7-1 antigen);CD80 antigen;CD80 molecule;CD80;Costimulatory factor CD80;costimulatory molecule variant IgV-CD80;CTLA-4 counter-receptor B7.1;LAB7;T-lymphocyte activation antigen CD80
UNIProt ID:
P33681

References

  • https://peerj.com/articles/8294/